Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.
2.
3.
4.
5.

Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.

Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW.

Clin Endocrinol (Oxf). 2003 Apr;58(4):428-35.

PMID:
12641625
6.

Assessment of the efficacy of iodine-131 for thyroid ablation.

Comtois R, Thériault C, Del Vecchio P.

J Nucl Med. 1993 Nov;34(11):1927-30.

7.

Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.

Tresoldi AS, Sburlati LF, Rodari M, Schinkelshoek M, Perrino M, De Leo S, Montefusco L, Colombo P, Arosio M, Lania AG, Fugazzola L, Chiti A.

J Endocrinol Invest. 2014 Aug;37(8):709-14. doi: 10.1007/s40618-014-0088-3.

PMID:
24844565
8.

Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.

Tsirona S, Vlassopoulou V, Tzanela M, Rondogianni P, Ioannidis G, Vassilopoulos C, Botoula E, Trivizas P, Datseris I, Tsagarakis S.

Clin Endocrinol (Oxf). 2014 Mar;80(3):459-63. doi: 10.1111/cen.12301.

PMID:
23895145
9.

Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.

Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW.

J Clin Endocrinol Metab. 2009 Nov;94(11):4171-9. doi: 10.1210/jc.2009-0869.

PMID:
19850694
10.
11.

The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.

Verkooijen RB, Verburg FA, van Isselt JW, Lips CJ, Smit JW, Stokkel MP.

Eur J Endocrinol. 2008 Sep;159(3):301-7. doi: 10.1530/EJE-08-0062.

12.

Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium.

Barbaro D, Grosso M, Boni G, Lapi P, Pasquini C, Orsini P, Turco A, Meucci G, Marzola MC, Berti P, Miccoli P, Mariani G, Rubello D.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):242-9. doi: 10.1007/s00259-009-1254-2.

PMID:
19760415
13.

Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.

Zidan J, Hefer E, Iosilevski G, Drumea K, Stein ME, Kuten A, Israel O.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1330-6.

PMID:
15275717
14.

Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.

Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY.

Am J Clin Oncol. 1998 Feb;21(1):77-81.

PMID:
9499265
15.
16.

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.

Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):457-80, x. doi: 10.1016/j.ecl.2008.02.007. Review.

PMID:
18502337
17.

Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.

Yoo D, Ajmal S, Gowda S, Machan J, Monchik J, Mazzaglia P.

World J Surg. 2012 Jun;36(6):1255-61. doi: 10.1007/s00268-012-1507-2.

PMID:
22430670
18.

Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.

Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A.

J Clin Endocrinol Metab. 2002 Sep;87(9):4063-8.

PMID:
12213846
19.

[Outcomes of long-term combined treatment in follicular thyroid carcinoma].

Baranauskas Z, Valuckas KP, Tiskevicius S.

Medicina (Kaunas). 2010;46(4):268-74. Lithuanian.

20.

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R.

J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137.

PMID:
23626005

Supplemental Content

Support Center